Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 biomarker-matched targeted combinations for relapsed or refractory pediatric ALL/LBL
MOH_2025-10-22_014396Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Sep 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax, dasatinib, ruxolitinib and trametinib in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and hematopoietic malignancies (3 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Phase 1 safety and tolerability, Phase 1 MTD/RP2D determination and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)hematopoietic malignancies
Beyond the preview
Go deeper on MOH_2025-10-22_014396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-22_014396.